Trials / Unknown
UnknownNCT06057025
Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.
Safety, Reactogenicity and Immunogenicity Study of the Drug "Sputnik Lite" for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Composition With Participation of Adult Volunteers.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Safety, reactogenicity and immunogenicity study of the drug "Sputnik Lite" for the prevention of coronavirus infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition | Single intramuscular injection of "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition. |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2023-09-28
- Last updated
- 2023-09-28
Source: ClinicalTrials.gov record NCT06057025. Inclusion in this directory is not an endorsement.